Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $15.53 million. The enterprise value is $12.05 million.
Market Cap | 15.53M |
Enterprise Value | 12.05M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 5.57 million shares outstanding. The number of shares has increased by 77.40% in one year.
Shares Outstanding | 5.57M |
Shares Change (YoY) | +77.40% |
Shares Change (QoQ) | +0.65% |
Owned by Insiders (%) | 3.49% |
Owned by Institutions (%) | 31.78% |
Float | 3.80M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 5.78 |
PS Ratio | 0.16 |
Forward PS | 0.40 |
PB Ratio | 0.47 |
P/FCF Ratio | 2.54 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.12 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 1.97 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.49.
Current Ratio | 1.11 |
Quick Ratio | 0.76 |
Debt / Equity | 0.49 |
Debt / EBITDA | n/a |
Debt / FCF | 2.62 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.50% and return on invested capital (ROIC) is -17.85%.
Return on Equity (ROE) | -49.50% |
Return on Assets (ROA) | -13.10% |
Return on Capital (ROIC) | -17.85% |
Revenue Per Employee | $656,653 |
Profits Per Employee | -$119,980 |
Employee Count | 150 |
Asset Turnover | 0.72 |
Inventory Turnover | 2.79 |
Taxes
In the past 12 months, Aytu BioPharma has paid $828,000 in taxes.
Income Tax | 828,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.18% in the last 52 weeks. The beta is -1.26, so Aytu BioPharma's price volatility has been lower than the market average.
Beta (1Y) | -1.26 |
52-Week Price Change | +8.18% |
50-Day Moving Average | 3.00 |
200-Day Moving Average | 2.50 |
Relative Strength Index (RSI) | 40.69 |
Average Volume (30 Days) | 21,548 |
Short Selling Information
The latest short interest is 360,854, so 6.48% of the outstanding shares have been sold short.
Short Interest | 360,854 |
Short Previous Month | 361,560 |
Short % of Shares Out | 6.48% |
Short % of Float | 9.50% |
Short Ratio (days to cover) | 15.90 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $98.50 million and -$18.00 million in losses. Loss per share was -$3.85.
Revenue | 98.50M |
Gross Profit | 62.29M |
Operating Income | -8.73M |
Pretax Income | -17.17M |
Net Income | -18.00M |
EBITDA | -8.45M |
EBIT | -17.17M |
Loss Per Share | -$3.85 |
Balance Sheet
The company has $19.53 million in cash and $16.04 million in debt, giving a net cash position of $3.49 million or $0.63 per share.
Cash & Cash Equivalents | 19.53M |
Total Debt | 16.04M |
Net Cash | 3.49M |
Net Cash Per Share | $0.63 |
Equity / Book Value | 32.85M |
Book Value Per Share | 5.90 |
Working Capital | 7.18M |
Cash Flow
Operating Cash Flow | 6.11M |
Capital Expenditures | n/a |
Free Cash Flow | 6.11M |
FCF Per Share | $1.11 |
Margins
Gross margin is 63.24%, with operating and profit margins of -8.86% and -18.27%.
Gross Margin | 63.24% |
Operating Margin | -8.86% |
Pretax Margin | -17.43% |
Profit Margin | -18.27% |
EBITDA Margin | -8.58% |
EBIT Margin | -17.43% |
FCF Margin | 6.21% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -77.40% |
Shareholder Yield | -77.40% |
Earnings Yield | -115.86% |
FCF Yield | 39.35% |
Analyst Forecast
The average price target for Aytu BioPharma is $12.50, which is 348.03% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.50 |
Price Target Difference | 348.03% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 2.87% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
Last Split Date | Jan 6, 2023 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -2.85 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.85 |
Piotroski F-Score | 5 |